Journal of Pharmaceutical Practice 2020;38(6):501-505

doi:10.12206/j.issn.1006-0111.202007031

The research progress on the efficacy enhancement of paclitaxel in chemotherapy for colorectal cancer

Bingchen CHEN 1 ; Enda YU 1

Affiliations

+expand

Keywords

paclitaxel; colorectal cancer; chemotherapy

Country

China

Language

Chinese

Abstract

Colorectal cancer is a malignant tumor with increasing incidence in China. Chemotherapy or neoadjuvant therapy are needed when the patients have deep tumor invasion of distant metastasis due to the hidden clinical manifestations and limited screening methods for the colorectal cancer. With many side effects of the current chemo-medications and the drug resistance, researchers are actively exploring new chemotherapy drugs for colorectal cancer. Paclitaxel is a first-line chemotherapy drug for the treatment of breast cancer, ovarian cancer, pancreatic cancer and other malignant tumors. Colorectal cancer cells are prone to become resistant to paclitaxel and the treatment efficiency was limited. However, new drug delivery systems and the combination drug therapy can enhance the treatment efficiency. This article reviews the effective treatment strategies of paclitaxel for colorectal cancer with the hope for new ideas and more effective chemotherapy.